FS KKR Capital logo

FS KKR Capital

FSK | NYSE
Chart Builder DCF Calculator
$11.57
-$0.15 (-1.28%)
At close: Nov 16, 2026, 4:00 PM ET
$11.55
-$0.02 (-0.17%)
After-hours: Nov 16, 2026, 6:11 PM ET
-1.28%

Rating

Updated: Nov 16, 2026
32.6
Fundamentals Weak
Market Sentiment Bullish
Moat Narrow
Sector Rank #1030/1269 (Top 81%)

Key Statistics

Market Data

Market Cap $3.16B
1D Range
11.53 11.80
52W Range
9.91 16.13

Valuation (TTM)

PE -6.25
PB 0.61
EV/EBITDA -108.07

Valuation (NTM)

Forward PE 6.89
Forward PEG 0.23
Price Target $12.00
Loading financial charts...

Profile

FS KKR Capital Corp. operates as a Business Development Company (BDC) with a primary investment focus on debt instruments. The firm delivers bespoke financing options specifically tailored for private...

Employees 1,383
IPO Date Apr 16, 2014
Fiscal Year January - December

Latest News

The IRS Takes Up to 37% of These 5 BDC Dividends (Unless You Move Them)

17 hours ago · 247wallst.com

The IRS Takes Up to 37% of These 5 BDC Dividends (Unless You Move Them)
FS KKR Capital Corp (FSK) Q3 2026 Earnings Call Transcript

10 days ago · seekingalpha.com

FS KKR Capital Corp (FSK) Q3 2026 Earnings Call Transcript
What FS KKR Capital (FSK) Said on Its Q3 Earnings Call

10 days ago · marketbeat.com

What FS KKR Capital (FSK) Said on Its Q3 Earnings Call
FS KKR Capital (FSK) Q3 Earnings and Revenues Beat Estimates

12 days ago · zacks.com

FS KKR Capital (FSK) Q3 Earnings and Revenues Beat Estimates
Dividend Harvesting Portfolio Week 296: $29,600 Allocated, $3,464 In Projected Dividends

15 days ago · seekingalpha.com

Dividend Harvesting Portfolio Week 296: $29,600 Allocated, $3,464 In Projected Dividends
Should Value Investors Buy FS KKR Capital Corp. (FSK) Stock?

19 days ago · zacks.com

Should Value Investors Buy FS KKR Capital Corp. (FSK) Stock?
ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease

25 days ago · gurufocus.com

ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease
15%+ Yields Trading At A 45% Discount

26 days ago · seekingalpha.com

15%+ Yields Trading At A 45% Discount
Are Investors Undervaluing FS KKR Capital Corp. (FSK) Right Now?

1 month ago · zacks.com

Are Investors Undervaluing FS KKR Capital Corp. (FSK) Right Now?
FS KKR Capital Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of FS KKR Capital Corp. - FSK

2 months ago · gurufocus.com

FS KKR Capital Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of FS KKR Capital Corp. - FSK

Earnings

Latest Earnings
Nov 5, 2026
EPS
$0.46
Beat +14.71%
REV
$294M
Beat +7.06%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Hold
Price Target
$12.00
Upside
+3.72%
Buy (0)
Hold (5)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.